Would you consider adding atezolizumab to a different chemotherapy/platinum-doublet backbone from the IMpower 133 trial for a new ES-SCLC patient?

No I would not, primarily for these reasons:

1) There are no clinical data of which I am aware regarding the addition of atezolizumab to irinotecan and cisplatin for any tumor type.

2) Irinotecan/cisplatin is more toxic than etoposide/platinum regimens, with no improvement in efficacy in 1L extensiv...